Study #2016-0859
A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients with Recurrent Malignant Glioma with a Hypermutator Phenotype
MD Anderson Study Status
Not Accepting
Treatment Agent
Pembrolizumab
Description
The purpose of this study is to test if the study drug called pembrolizumab could control the growth or shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by half, or prevent it from growing for at least 6 months. Pembrolizumab is an antibody that targets the immune system and activates it to stop cancer growth and/or kill cancer cells.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Glioma, Recurrent Malignant Glioma
Study phase:
Not applicable
Physician name:
Carlos Kamiya Matsuoka
Department:
Neuro-Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.